Antioxidative Properties and Effect of Quercetin and Its Glycosylated Form (Rutin) on Acetylcholinesterase and Butyrylcholinesterase Activities

Journal of Evidence-Based Complementary and Alternative Medicine

Volumn 21, Issue 4, 2016, Pages NP11-NP17

  Ademosun, Ayokunle O ^a   Oboh, Ganiyu ^a   Bello, Fatai ^a   Ayeni, Peluola O ^a  

^a FEDERAL UNIVERSITY OF TECHNOLOGY   (Nigeria)

Author keywords

acetylcholinesterase; Alzheimer s disease; antioxidant; butyrylcholinesterase

Indexed keywords

ACETYLCHOLINESTERASE; ANTIOXIDANT; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; QUERCETIN; RUTOSIDE;

ANIMAL; BRAIN CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; LIPID PEROXIDATION; METABOLISM; RAT;

ACETYLCHOLINESTERASE; ANIMALS; ANTIOXIDANTS; BRAIN CHEMISTRY; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; LIPID PEROXIDATION; QUERCETIN; RATS; RUTIN;

EID: 84989237202     PISSN: 21565872     EISSN: None     Source Type: Journal    
DOI: 10.1177/2156587215610032     Document Type: Article

References (29)

1. Bell C, Moosmann B. Oxidative nerve cell death in Alzheimer’s disease and stroke: antioxidants as neuroprotective compounds. Biol Chem. 2002;383:521–536.
2. Ramassamy C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur J Pharmacol. 2006;545:51–64.
3. Orhan I, Kartal M, Tosun F, Sener B. Screening of various phenolic acids and flavonoid derivatives for their anticholinesterase potential. Z Naturforsch C. 2007;62:829–832.
4. Jung M, Park M. Acetylcholinesterase inhibition by flavonoids from Agrimonia pilosa. Molecules. 2007;12:2130–2139.
5. Bonda DJ, Wang X, Perry G. Oxidative stress in Alzheimer disease: a possibility for prevention. Neuropharmacology. 2010;59:290–294.
6. Mancinelli R, Barlocci E, Palminiello S, Saso L. Oxidative stress and brain diseases: biomarkers and analytics methodologies. Indian J Biotechnol. 2011;10:395–403.
7. Facecchia K, Fochesato L, Ray SD, Stohs SJ, Pandey S. Oxidative toxicity in neurodegenerative diseases: role of mitochondrial dysfunction and therapeutic strategies. J Toxicol. 2011;2011:683728. doi:10.1155/2011/683728.
8. Reed TT, Owen J, Pierce WM, Sebastian A, Sullivan PG, Butterfield DA. Proteomic identification of nitrated brain proteins in traumatic brain-injured rats treated post injury with gamma-glutamylcysteine ethyl ester: insights into the role of elevation of glutathione as a potential therapeutic strategy for traumatic brain injury. J Neurosci Res. 2009;87:408–417.
9. Sultana R, Butterfield DA. Role of oxidative stress in the progression of Alzheimer’s disease. J Alzheimers Dis. 2010;19:341–353.
10. Mehta M, Adem A, Sabbagh M. New acetylcholinesterase inhibitors for Alzheimer’s disease. Int J Alzheimers Dis. 2012;2012:728983. doi:10.1155/2012/728983.
11. Fallarero A, Oinonen P, Gupta S. Inhibition of acetylcholinesterase by coumarins: the case of coumarin 106. Pharmacol Res. 2008;58:215–221.
12. Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol. 2006;9:101–124.
13. dos Santos Pisoni D, Sobieski da Costa J, Gamba D. Synthesis and AChE inhibitory activity of new chiral tetrahydroacridine analogues from terpenic cyclanones. Eur J Med Chem. 2010;45:526–535.
14. Baková Z, Kolesárová A. Bioflavonoid quercetin-food sources, bioavailability, absorbtion and effect on animal cells. J Microbiol Biotechnol Food Sci. 2012;2:426–433.
15. Manach C, Morand C, Demigné C, Texier O, Régérat F, Rémésy C. Bioavailability of rutin and quercetin in rats. FEBS Lett. 1997;409:12–16.
16. Perry NS, Houghton PJ, Theobald A, Jenner P, Perry EK. In-vitro inhibition of human erythrocyte acetylcholinesterase by salvia lavandulaefolia essential oil and constituent terpenes. J Pharmacol. 2000;52:895–902.
17. Susanta K, Chakraborty G, Gupta M, Mazumder U. In vitro antioxidant activity of Diospyros malabarica Kostel bark. Indian J Exp Biol. 2004;44:39–44.
18. Halliwell B, Gutteridge JM, Aruoma OI. The deoxyribose method: simple “test-tube” assay for determination of rate constants for reactions of hydroxyl radicals. Anal Biochem. 1987;165:215–219.
19. 2+-dependent lipid peroxidation. Free Radic Biol Med. 1987;3:379–387.
20. Belle NA, Dalmolin GD, Fonini G, Rubim MA, Rocha JBT. Polyamines reduce lipid peroxidation induced by different pro-oxidant agents. Brain Res. 2004;1008:245–251.
21. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351–358.
22. Shanks M, Kivipelto M, Bullock R, Lane R. Cholinesterase inhibition: is there evidence for disease-modifying effects? Curr Med Res Opin. 2009;25:2439–2446.
23. Khan MTH, Orhan I, Senol FSS. Cholinesterase inhibitory activities of some flavonoid derivatives and chosen xanthone and their molecular docking studies. Chem Biol Interact. 2009;181:383–389.
24. Katalinic M, Rusak G, Domacinovic Barovic J. Structural aspects of flavonoids as inhibitors of human butyrylcholinesterase. Eur J Med Chem. 2010;45:186–192.
25. Ji HF, Zhang HY. Theoretical evaluation of flavonoids as multipotent agents to combat Alzheimer’s disease. J Mol Struct: Theochem. 2006;767:3–9.
26. Bekir J, Mars M, Souchard JP, Bouajila J. Assessment of antioxidant, anti-inflammatory, anti-cholinesterase and cytotoxic activities of pomegranate (Punica granatum) leaves. Food Chem Toxicol. 2013;55:470–475.
27. Bush AI. Metal complexing agents as therapies for Alzheimer’s disease. Neurobiol Aging. 2002;23:1031–1038.
28. Huang WH, Lv D, Yu HP. Dual-target-directed 1,3-diphenylurea derivatives: BACE 1 inhibitor and metal chelator against Alzheimer’s disease. Bioorg Med Chem. 2010;18:5610–5615.
29. Janisch KM, Williamson G, Needs P, Plumb GW. Properties of quercetin conjugates: modulation of LDL oxidation and binding to human serum albumin. Free Radic Res. 2004;38:877–884.